Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients
Expanded access is currently available for this treatment.
Verified by APT Pharmaceuticals, Inc., April 2008
Sponsored by: APT Pharmaceuticals, Inc.
Information provided by: APT Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00633373
  Purpose

Currently there are no approved therapies for lung transplant recipients in the United States (US). Treatment with CIS following lung transplantation has previously been demonstrated to result in a clinically meaningful improvement in survival and chronic rejection-free survival compared to placebo, but additional data supporting its use is needed prior to Food and Drug Administration (FDA) approval. This treatment use protocol is a mechanism for providing eligible lung transplant recipients early access to CIS in advance of FDA approval.


Condition Intervention
Lung Transplant
Drug: Cyclosporine Inhalation Solution

MedlinePlus related topics: Lung Transplantation
Drug Information available for: Cyclosporin Cyclosporine
U.S. FDA Resources
Study Type:
Expanded Access
Official Title:
An Open-Label Treatment Use Protocol of Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

Further study details as provided by APT Pharmaceuticals, Inc.:

Intervention Details:
    Drug: Cyclosporine Inhalation Solution
    Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
  Eligibility
Genders Eligible for Study:
Both
Criteria

Inclusion Criteria:

  • Single-or double-lung transplant recipients.

Exclusion Criteria:

  • Known hypersensitivity to cyclosporine or propylene glycol (PG)
  • Females who are pregnant or are considering becoming pregnant
  • Females who are breast feeding a child.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00633373

Contacts
Contact: Charles Johnson, MB, ChB 650-483-9531 charliej@aptbio.com
Contact: Wendy Verret, MPH 650-931-1666 ext 117 wverret@aptbio.com

Locations
United States, California
University of California at San Francisco
San Francisco, California, United States, 94143
United States, Florida
Nemour's Children's Clinic
Orlando, Florida, United States, 32801
United States, Maryland
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
APT Pharmaceuticals, Inc.
  More Information

Publications:
Burkart GJ, Smaldone GC, Eldon MA, Venkataramanan R, Dauber J, Zeevi A, McCurry K, McKaveney TP, Corcoran TE, Griffith BP, Iacono AT. Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm Res. 2003 Feb;20(2):252-6.
Iacono AT, Smaldone GC, Keenan RJ, Diot P, Dauber JH, Zeevi A, Burckart GJ, Griffith BP. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med. 1997 May;155(5):1690-8.
Keenan RJ, Iacono A, Dauber JH, Zeevi A, Yousem SA, Ohori NP, Burckart GJ, Kawai A, Smaldone GC, Griffith BP. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg. 1997 Feb;113(2):335-40; discussion 340-1.
Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W, Burckart G, Smaldone G, Pham S, Ohori NP, Yousem S, Williams P, Griffith B, Zeevi A. Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation. 1997 Jul 27;64(2):263-9.
Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006 Jan 12;354(2):141-50.
Iacono AT, Corcoran TE, Griffith BP, Grgurich WF, Smith DA, Zeevi A, Smaldone GC, McCurry KR, Johnson BA, Dauber JH. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J. 2004 Mar;23(3):384-90.
Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, Ohori NP, Grgurich WF, Burckart GJ, Zeevi A, Delgado E, O'Riordan TG, Zendarsky MM, Yousem SA, Griffith BP. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1451-5.

Responsible Party:
APT Pharmaceutical Inc. ( Charles Johnson, MB. ChB. )
Study ID Numbers:
ACS004
First Received:
March 5, 2008
Last Updated:
April 23, 2008
ClinicalTrials.gov Identifier:
NCT00633373  
Health Authority:
United States: Food and Drug Administration

Keywords provided by APT Pharmaceuticals, Inc.:
lung
transplant
transplant rejection
Cyclosporine
bronchiolitis obliterans

Study placed in the following topic categories:
Cyclosporine
Clotrimazole
Miconazole
Bronchiolitis
Tioconazole
Cyclosporins
Bronchiolitis Obliterans

Additional relevant MeSH terms:
Anti-Infective Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antifungal Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 07, 2009